Wednesday, September 28, 2016

Zarontin


Zarontin is a brand name of ethosuximide, approved by the FDA in the following formulation(s):


ZARONTIN (ethosuximide - capsule; oral)



  • Manufacturer: PARKE DAVIS

    Approved Prior to Jan 1, 1982

    Strength(s): 250MG [RLD][AB]

Has a generic version of Zarontin been approved?


Yes. The following products are equivalent to Zarontin:


ethosuximide capsule; oral



  • Manufacturer: BANNER PHARMACAPS

    Approval date: October 28, 2002

    Strength(s): 250MG [AB]


  • Manufacturer: VERSAPHARM

    Approval date: May 28, 2008

    Strength(s): 250MG [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zarontin. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Zarontin.

See also...

  • Zarontin Consumer Information (Wolters Kluwer)
  • Zarontin Solution Consumer Information (Wolters Kluwer)
  • Zarontin Consumer Information (Cerner Multum)
  • Zarontin Advanced Consumer Information (Micromedex)
  • Zarontin AHFS DI Monographs (ASHP)
  • Ethosuximide Consumer Information (Wolters Kluwer)
  • Ethosuximide Solution Consumer Information (Wolters Kluwer)
  • Ethosuximide Consumer Information (Cerner Multum)
  • Ethosuximide Advanced Consumer Information (Micromedex)
  • Ethosuximide AHFS DI Monographs (ASHP)

Ultram ER


See also: Generic Ultram


Ultram ER is a brand name of tramadol, approved by the FDA in the following formulation(s):


ULTRAM ER (tramadol hydrochloride - tablet, extended release; oral)



  • Manufacturer: VALEANT INTL

    Approval date: September 8, 2005

    Strength(s): 100MG [RLD][AB1], 200MG [AB1], 300MG [AB1]

Has a generic version of Ultram ER been approved?


Yes. The following products are equivalent to Ultram ER:


tramadol hydrochloride tablet, extended release; oral



  • Manufacturer: LUPIN LTD

    Approval date: August 29, 2011

    Strength(s): 100MG [AB1], 200MG [AB1], 300MG [AB1]


  • Manufacturer: PAR PHARM

    Approval date: November 13, 2009

    Strength(s): 100MG [AB1], 200MG [AB1]


  • Manufacturer: PAR PHARM

    Approval date: September 20, 2011

    Strength(s): 300MG [AB1]


  • Manufacturer: SUN PHARMA GLOBAL

    Approval date: December 7, 2011

    Strength(s): 100MG [AB1], 200MG [AB1], 300MG [AB1]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Ultram ER. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Ultram ER.

See also...

  • Ultram ER Extended-Release Tablets Consumer Information (Wolters Kluwer)
  • Ultram ER Consumer Information (Cerner Multum)
  • Ultram ER Advanced Consumer Information (Micromedex)
  • Tramadol Consumer Information (Drugs.com)
  • Tramadol Consumer Information (Wolters Kluwer)
  • Tramadol Extended-Release Capsules Consumer Information (Wolters Kluwer)
  • Tramadol Extended-Release Tablets Consumer Information (Wolters Kluwer)
  • Tramadol Orally Disintegrating Tablets Consumer Information (Wolters Kluwer)
  • Tramadol Consumer Information (Cerner Multum)
  • FusePaq Synapryn Advanced Consumer Information (Micromedex)
  • Tramadol Advanced Consumer Information (Micromedex)
  • Tramadol Hydrochloride AHFS DI Monographs (ASHP)

Tri-Luma


Tri-Luma is a brand name of fluocinolone/hydroquinone/tretinoin topical, approved by the FDA in the following formulation(s):


TRI-LUMA (fluocinolone acetonide; hydroquinone; tretinoin - cream; topical)



  • Manufacturer: GALDERMA LABS LP

    Approval date: January 18, 2002

    Strength(s): 0.01%;4%;0.05% [RLD]

Has a generic version of Tri-Luma been approved?


No. There is currently no therapeutically equivalent version of Tri-Luma available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Tri-Luma. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Topical skin care composition
    Patent 7,915,243
    Issued: March 29, 2011
    Inventor(s): Puglia; Nancy & Ramirez; Rosario & Roth; Jerry
    Assignee(s): Galderma S.A.
    A cream base for the topical application of skin care therapeutics and a process for making the cream base. In one embodiment, the therapeutic is tretinoin, hydroquinone and fluocinolone acetonide for the treatment of hyperpigmented skin conditions, such as melasma.
    Patent expiration dates:

    • March 22, 2026
      ✓ 
      Drug product




  • Topical skin care composition
    Patent 7,939,516
    Issued: May 10, 2011
    Inventor(s): Puglia; Nancy & Roth; Jerry & Ramirez; Rosario
    Assignee(s): Galderma S.A.
    A cream base for the topical application of skin care therapeutics and a process for making the cream base. In one embodiment, the therapeutic is tretinoin, hydroquinone and fluocinolone acetonide for the treatment of hyperpigmented skin conditions, such as melasma.
    Patent expiration dates:

    • May 4, 2025
      ✓ 
      Drug product



See also...

  • Tri-Luma Consumer Information (Wolters Kluwer)
  • Tri-Luma Consumer Information (Cerner Multum)
  • Fluocinolone/Hydroquinone/Tretinoin Consumer Information (Wolters Kluwer)
  • Fluocinolone, hydroquinone, and tretinoin topical Consumer Information (Cerner Multum)

Diogam




Diogam may be available in the countries listed below.


Ingredient matches for Diogam



Diosmin

Diosmin is reported as an ingredient of Diogam in the following countries:


  • Tunisia

International Drug Name Search

femhrt


femhrt is a brand name of ethinyl estradiol/norethindrone, approved by the FDA in the following formulation(s):


FEMHRT (ethinyl estradiol; norethindrone acetate - tablet; oral)



  • Manufacturer: WARNER CHILCOTT

    Approval date: October 15, 1999

    Strength(s): 0.005MG;1MG [RLD][AB]


  • Manufacturer: WARNER CHILCOTT

    Approval date: January 14, 2005

    Strength(s): 0.0025MG;0.5MG

Has a generic version of femhrt been approved?


Yes. The following products are equivalent to femhrt:


NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL (ethinyl estradiol; norethindrone acetate tablet; oral)



  • Manufacturer: BARR

    Approval date: November 6, 2009

    Strength(s): 0.005MG;1MG [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of femhrt. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with femhrt.

See also...

  • Femhrt Consumer Information (Drugs.com)
  • Femhrt Consumer Information (Wolters Kluwer)
  • Femhrt 1 mg/5 mcg HRT Consumer Information (Cerner Multum)
  • Femhrt 1/5 HRT Consumer Information (Cerner Multum)
  • Femhrt HRT Consumer Information (Cerner Multum)
  • Ortho-Novum Consumer Information (Drugs.com)
  • Norethindrone/Ethinyl Estradiol Consumer Information (Wolters Kluwer)
  • Norethindrone/Ethinyl Estradiol (HRT) Consumer Information (Wolters Kluwer)
  • Norethindrone/Ethinyl Estradiol Chewable Tablets Consumer Information (Wolters Kluwer)
  • Norethindrone/Ethinyl Estradiol Tablets Consumer Information (Wolters Kluwer)
  • Ethinyl estradiol and norethindrone Consumer Information (Cerner Multum)
  • Ethinyl estradiol and norethindrone HRT Consumer Information (Cerner Multum)
  • Norethindrone, ethinyl estradiol, and ferrous fumarate Advanced Consumer Information (Micromedex)

Pataday


Pataday is a brand name of olopatadine ophthalmic, approved by the FDA in the following formulation(s):


PATADAY (olopatadine hydrochloride - solution/drops; ophthalmic)



  • Manufacturer: ALCON PHARMS LTD

    Approval date: December 22, 2004

    Strength(s): EQ 0.2% BASE [RLD]

Has a generic version of Pataday been approved?


No. There is currently no therapeutically equivalent version of Pataday available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Pataday. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Topical ophthalmic formulations for treating allergic eye diseases
    Patent 5,641,805
    Issued: June 24, 1997
    Inventor(s): Hayakawa; Eiji & Nakakura; Masashi & Robertson; Stella M. & Yanni; John Michael
    Assignee(s): Alcon Laboratories, Inc.
    Kyowa Hakko Kogyo Co. Ltd.
    Topical ophthalmic formulations of the invention contain as an active ingredient 11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid or a pharmaceutically acceptable salt thereof. The formulations are useful for treating allergic eye diseases such as allergic conjunctivitis, vernal conjunctivitis, vernal keratoconjunctivitis, and giant papillary conjunctivitis.
    Patent expiration dates:

    • June 6, 2015
      ✓ 
      Patent use: METHOD OF TREATING ALLERGIC CONJUNCTIVITIS


    • December 6, 2015
      ✓ 
      Pediatric exclusivity




  • Olopatadine formulations for topical administration
    Patent 6,995,186
    Issued: February 7, 2006
    Inventor(s): Castillo; Ernesto J. & Han; Wesley Wehsin & Zhang; Huixiang & Bhagat; Haresh G. & Singh; Onkar N. & Bullock; Joseph Paul & Dixit; Suresh C.
    Assignee(s): Alcon, Inc.
    Topical formulations of olopatadine for treatment of allergic or inflammatory disorders of the eye and nose are disclosed. The aqueous formulations contain approximately 0.17-0.62% (w/v) of olopatadine and an amount of polyvinylpyrrolidone or polystyrene sulfonic acid sufficient to enhance the physical stability of the formulations.
    Patent expiration dates:

    • November 12, 2023
      ✓ 
      Patent use: METHOD OF TREATING ALLERGIC CONJUNCTIVITIS
      ✓ 
      Drug product


    • May 12, 2024
      ✓ 
      Pediatric exclusivity




  • Olopatadine formulations for topical administration
    Patent 7,402,609
    Issued: July 22, 2008
    Inventor(s): Castillo; Ernesto J. & Han; Wesley Wehsin & Zhang; Huixiang & Bhagat; Haresh G. & Singh; Onkar N. & Bullock; Joseph Paul & Dixit; Suresh C.
    Assignee(s): Alcon, Inc.
    Topical formulations of olopatadine for treatment of allergic or inflammatory disorders of the eye and nose are disclosed. The aqueous formulations contain approximately 0.17-0.62% (w/v) of olopatadine and an amount of polyvinylpyrrolidone or polystyrene sulfonic acid sufficient to enhance the physical stability of the formulations.
    Patent expiration dates:

    • June 19, 2022
      ✓ 
      Drug product


    • December 19, 2022
      ✓ 
      Pediatric exclusivity



See also...

  • Pataday Drops Consumer Information (Wolters Kluwer)
  • Pataday Consumer Information (Cerner Multum)
  • Pataday Advanced Consumer Information (Micromedex)
  • Olopatadine Drops Consumer Information (Wolters Kluwer)
  • Olopatadine ophthalmic Consumer Information (Cerner Multum)
  • Olopatadine Ophthalmic Advanced Consumer Information (Micromedex)
  • Olopatadine Hydrochloride AHFS DI Monographs (ASHP)

Jalyn


Jalyn is a brand name of dutasteride/tamsulosin, approved by the FDA in the following formulation(s):


JALYN (dutasteride; tamsulosin hydrochloride - capsule; oral)



  • Manufacturer: GLAXOSMITHKLINE

    Approval date: June 14, 2010

    Strength(s): 0.5MG;0.4MG [RLD]

Has a generic version of Jalyn been approved?


No. There is currently no therapeutically equivalent version of Jalyn available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Jalyn. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Androstenone derivative
    Patent 5,565,467
    Issued: October 15, 1996
    Inventor(s): Batchelor; Kenneth W. & Frye; Stephen V. & Dorsey, Jr.; George F. & Mook, Jr.; Robert A.
    Assignee(s): Glaxo Wellcome Inc.
    The present invention relates to the compound of formula (I), ##STR1## also known as 17.beta.-N-(2,5-bis(Trifluoromethyl))phenylcarbamoyl-4-aza-5.alpha.-andros t-1-en-3-one, solvates thereof, its preparation, intermediates used in its preparation, pharmaceutical formulations thereof and its use in the treatment of androgen responsive and mediated diseases.
    Patent expiration dates:

    • November 20, 2015
      ✓ 
      Drug substance
      ✓ 
      Drug product




  • Androstenone derivative
    Patent 5,846,976
    Issued: December 8, 1998
    Inventor(s): Batchelor; Kenneth William & Frye; Stephen Vernon & Dorsey, Jr.; George F. & Mook, Jr.; Robert A.
    Assignee(s): Glaxo Wellcome Inc.
    The present invention relates to the compound of formula (I), ##STR1## also known as 17.beta.-N-(2,5-bis(Trifluoromethyl))phenylcarbamoyl-4-aza-5.alpha.-andros t-1-en-3-one, solvates thereof, its preparation, intermediates used in its preparation, pharmaceutical formulations thereof and its use in the treatment of androgen responsive and mediated diseases.
    Patent expiration dates:

    • September 17, 2013
      ✓ 
      Patent use: METHOD OF TREATING ANDROGEN RESPONSIVE OR MEDICATED CONDITION IN A MAMMAL BY ADMINISTERING A SAFE & EFFECTIVE AMOUNT OF DUTASTERIDE OR A PHARMACEUTICALLY ACCEPTABLE SOLVATE THEREOF.. CONDITIONS INCLUDE BENIGN PROSTATIC HYPERTROPHY




  • Androstenones
    Patent 5,998,427
    Issued: December 7, 1999
    Inventor(s): Batchelor; Kenneth William & Frye; Stephen Vernon
    Assignee(s): Glaxo Wellcome Inc.
    The present invention relates to compounds of formula (I), wherein carbons 1 and 2 are joined by either a single or a double bond; R.sup.1 is hydrogen or methyl; R.sup.2 is hydrogen or methyl; R.sup.3 is (B) wherein X, R.sup.6, R.sup.7 and R.sup.8 are various groups, and pharmaceutically acceptable solvates thereof and their use in the treatment of androgen responsive and mediated diseases. ##STR1##
    Patent expiration dates:

    • September 17, 2013
      ✓ 
      Patent use: METHOD OF TREATING AN ANDROGEN RESPONSE OR MEDIATED DISEASE IN A MAMMAL BY ADMININSTERING AN EFFECTIVE ANDROGEN RESPONSIVE OR MEDICATED DISEASE AMOUNT OF DUTASTERIDE..CONDITIONS INCLUDE BENIGN PROSTATIC HYPERPLASIA
      ✓ 
      Drug substance
      ✓ 
      Drug product



See also...

  • Jalyn Consumer Information (Drugs.com)
  • Jalyn Consumer Information (Wolters Kluwer)
  • Jalyn Consumer Information (Cerner Multum)
  • Jalyn Advanced Consumer Information (Micromedex)
  • Dutasteride/Tamsulosin Consumer Information (Wolters Kluwer)
  • Dutasteride and tamsulosin Consumer Information (Cerner Multum)
  • Dutasteride and tamsulosin Advanced Consumer Information (Micromedex)

Asniton




Asniton may be available in the countries listed below.


Ingredient matches for Asniton



Betahistine

Betahistine dihydrochloride (a derivative of Betahistine) is reported as an ingredient of Asniton in the following countries:


  • Russian Federation

International Drug Name Search

Cutar Emulsion Topical


Generic Name: coal tar (Topical route)


kole tar


Commonly used brand name(s)

In the U.S.


  • Betatar Gel

  • Cutar Emulsion

  • Denorex

  • DHS Tar

  • Doak Tar

  • Duplex T

  • Fototar

  • Ionil-T Plus

  • Medotar

  • MG 217

  • Neutrogena T/Derm

  • Neutrogena T/Gel

In Canada


  • Estar

  • Liquor Carbonis Detergens

  • Psorigel

  • Spectro Tar Skin Wash

  • Tar Distillate

Available Dosage Forms:


  • Liquid

  • Shampoo

  • Lotion

  • Solution

  • Cream

  • Gel/Jelly

  • Soap

  • Kit

  • Ointment

  • Bar

  • Foam

  • Emulsion

Therapeutic Class: Keratolytic


Uses For Cutar Emulsion


Coal tar is used to treat eczema, psoriasis, seborrheic dermatitis, and other skin disorders.


Some of these preparations are available only with your doctor's prescription.


Before Using Cutar Emulsion


In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following should be considered:


Allergies


Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.


Pediatric


Coal tar products should not be used on infants, unless otherwise directed by your doctor. Studies on this medicine have been done only in adult patients, and there is no specific information comparing use of this medicine in children with use in other age groups.


Geriatric


Many medicines have not been studied specifically in older people. Therefore, it may not be known whether they work exactly the same way they do in younger adults or if they cause different side effects or problems in older people. There is no specific information comparing use of this medicine in the elderly with use in other age groups.


Breast Feeding


Studies in women suggest that this medication poses minimal risk to the infant when used during breastfeeding.


Interactions with Medicines


Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. Tell your healthcare professional if you are taking any other prescription or nonprescription (over-the-counter [OTC]) medicine.


Interactions with Food/Tobacco/Alcohol


Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. Discuss with your healthcare professional the use of your medicine with food, alcohol, or tobacco.


Proper Use of coal tar

This section provides information on the proper use of a number of products that contain coal tar. It may not be specific to Cutar Emulsion. Please read with care.


Use this medicine only as directed. Do not use more of it and do not use it more often than recommended on the label, unless otherwise directed by your doctor. To do so may increase the chance of side effects.


After applying coal tar, protect the treated area from direct sunlight and do not use a sunlamp for 72 hours, unless otherwise directed by your doctor, since a severe reaction may occur. Also, make sure you have removed all the coal tar medicine from your skin before you go back into direct sunlight or use a sunlamp.


Do not apply this medicine to infected, blistered, raw, or oozing areas of the skin.


Keep this medicine away from the eyes. If you should accidentally get some in your eyes, flush them thoroughly with water at once.


To use the cream or ointment form of this medicine:


  • Apply enough medicine to cover the affected area, and rub in gently.

To use the gel form of this medicine:


  • Apply enough gel to cover the affected area, and rub in gently. Allow the gel to remain on the affected area for 5 minutes, then remove excess gel by patting with a clean tissue.

To use the shampoo form of this medicine:


  • Wet the scalp and hair with lukewarm water. Apply a generous amount of shampoo and rub into the scalp, then rinse. Apply the shampoo again, working up a rich lather, and allow to remain on the scalp for 5 minutes. Then rinse thoroughly.

To use the nonshampoo liquid form of this medicine:


  • Some of these preparations are to be applied directly to dry or wet skin, some are to be added to lukewarm bath water, and some may be applied directly to dry or wet skin or added to lukewarm bath water. Make sure you know exactly how you should use this medicine. If you have any questions about this, check with your health care professional.

  • If this medicine is to be applied directly to the skin, apply enough to cover the affected area, and rub in gently.

  • Some of these preparations contain alcohol and are flammable. Do not use near heat, near open flame, or while smoking.

Dosing


The dose of this medicine will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of this medicine. If your dose is different, do not change it unless your doctor tells you to do so.


The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.


  • For eczema, psoriasis, seborrheic dermatitis, and other skin disorders:
    • For cleansing bar dosage form:
      • Adults—Use one or two times a day, or as directed by your doctor.

      • Children—Use and dose must be determined by your doctor.


    • For cream dosage form:
      • Adults—Apply to the affected area(s) of the skin up to four times a day.

      • Children—Use and dose must be determined by your doctor.


    • For gel dosage form:
      • Adults—Apply to the affected area(s) of the skin one or two times a day.

      • Children—Use and dose must be determined by your doctor.


    • For lotion dosage form:
      • Adults—Apply directly to the affected area(s) of the skin or use as a bath, hand or foot soak, or as a hair rinse, depending on the product.

      • Children—Use and dose must be determined by your doctor.


    • For ointment dosage form:
      • Adults—Apply to the affected area(s) of the skin two or three times a day.

      • Children—Use and dose must be determined by your doctor.


    • For shampoo dosage form:
      • Adults—Use once a day to once a week or as directed by your doctor.

      • Children—Use and dose must be determined by your doctor.


    • For topical solution dosage form:
      • Adults—Apply to wet the skin or scalp, or use as a bath, depending on the product.

      • Children—Use and dose must be determined by your doctor.


    • For topical suspension dosage form:
      • Adults—Use as a bath.

      • Children—Use and dose must be determined by your doctor.



Missed Dose


If you miss a dose of this medicine, apply it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule.


Storage


Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light. Keep from freezing.


Keep out of the reach of children.


Do not keep outdated medicine or medicine no longer needed.


Precautions While Using Cutar Emulsion


If this medicine is used on the scalp, it may temporarily discolor blond, bleached, or tinted hair.


Coal tar may stain the skin or clothing. Avoid getting it on your clothing. The stain on the skin will wear off after you stop using the medicine.


Cutar Emulsion Side Effects


In animal studies, coal tar has been shown to increase the chance of skin cancer.


Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.


Check with your doctor as soon as possible if any of the following side effects occur:


Rare
  • Skin irritation not present before use of this medicine

  • skin rash

Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:


More common
  • Stinging (mild)—especially for gel and solution dosage forms

Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.


Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.



The information contained in the Thomson Reuters Micromedex products as delivered by Drugs.com is intended as an educational aid only. It is not intended as medical advice for individual conditions or treatment. It is not a substitute for a medical exam, nor does it replace the need for services provided by medical professionals. Talk to your doctor, nurse or pharmacist before taking any prescription or over the counter drugs (including any herbal medicines or supplements) or following any treatment or regimen. Only your doctor, nurse, or pharmacist can provide you with advice on what is safe and effective for you.


The use of the Thomson Reuters Healthcare products is at your sole risk. These products are provided "AS IS" and "as available" for use, without warranties of any kind, either express or implied. Thomson Reuters Healthcare and Drugs.com make no representation or warranty as to the accuracy, reliability, timeliness, usefulness or completeness of any of the information contained in the products. Additionally, THOMSON REUTERS HEALTHCARE MAKES NO REPRESENTATION OR WARRANTIES AS TO THE OPINIONS OR OTHER SERVICE OR DATA YOU MAY ACCESS, DOWNLOAD OR USE AS A RESULT OF USE OF THE THOMSON REUTERS HEALTHCARE PRODUCTS. ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE OR USE ARE HEREBY EXCLUDED. Thomson Reuters Healthcare does not assume any responsibility or risk for your use of the Thomson Reuters Healthcare products.


More Cutar Emulsion Topical resources


  • Cutar Emulsion Topical Use in Pregnancy & Breastfeeding
  • Cutar Emulsion Topical Support Group
  • 1 Review for Cutar Topical - Add your own review/rating


Compare Cutar Emulsion Topical with other medications


  • Dermatitis
  • Psoriasis
  • Seborrheic Dermatitis

Gleevec


Gleevec is a brand name of imatinib, approved by the FDA in the following formulation(s):


GLEEVEC (imatinib mesylate - tablet; oral)



  • Manufacturer: NOVARTIS

    Approval date: April 18, 2003

    Strength(s): EQ 100MG BASE, EQ 400MG BASE [RLD]

Has a generic version of Gleevec been approved?


No. There is currently no therapeutically equivalent version of Gleevec available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Gleevec. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Pyrimidine derivatives and processes for the preparation thereof
    Patent 5,521,184
    Issued: May 28, 1996
    Inventor(s): Zimmermann; Jurg
    Assignee(s): Ciba-Geigy Corporation
    There are described N-phenyl-2-pyrimidine-amine derivatives of formula I ##STR1## wherein R.sub.1 is 4-pyrazinyl, 1-methyl-1H-pyrrolyl, amino- or amino-lower alkyl-substituted phenyl wherein the amino group in each case is free, alkylated or acylated, 1H-indolyl or 1H-imidazolyl bonded at a five-membered ring carbon atom, or unsubstituted or lower alkyl-substituted pyridyl bonded at a ring carbon atom and unsubstituted or substituted at the nitrogen atom by oxygen, R.sup.2, R.sup.3, R.sup.9, X, Y, n and R.sup.10 are defined in claim 1 These compounds can be used, for example, in the therapy of tumoral diseases.
    Patent expiration dates:

    • January 4, 2015
      ✓ 
      Drug substance
      ✓ 
      Drug product


    • January 4, 2015
      ✓ 
      Patent use: A METHOD FOR TREATING A TUMOR DISEASE
      ✓ 
      Drug substance
      ✓ 
      Drug product


    • January 4, 2015


    • July 4, 2015
      ✓ 
      Pediatric exclusivity




  • Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
    Patent 6,894,051
    Issued: May 17, 2005
    Inventor(s): Zimmermann; Jürg & Sutter; Bertrand & Bürger; Hans Michael
    Assignee(s): Novartis AG
    The invention relates to a new crystalline form of the methanesulfonic acid addition salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]benzamide of formula 1, which may be used for example for tumor therapy.
    Patent expiration dates:

    • May 23, 2019
      ✓ 
      Patent use: A METHOD FOR TREATING A TUMOR DISEASE
      ✓ 
      Drug substance
      ✓ 
      Drug product


    • November 23, 2019
      ✓ 
      Pediatric exclusivity




  • Treatment of gastrointestinal stromal tumors
    Patent 6,958,335
    Issued: October 25, 2005
    Inventor(s): Buchdunger; Elisabeth & Capdeville; Renaud & Demetri; George Daniel & Dimitrijevic; Sasa & Druker; Brian Jay & Fletcher; Jonathan A. & Heinrich; Michael C. & Joensuu; Heikki & Silberman; Sandra Leta & Tuveson; David
    Assignee(s): Novartis AG
    Dana-Farber Cancer Institute, Inc.
    Oregon Health & Science University
    4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of the formula I or a pharmaceutically acceptable salt thereof can be used in the treatment of gastrointestinal stromal tumours.
    Patent expiration dates:

    • December 19, 2021
      ✓ 
      Patent use: GLEEVEC IS ALSO INDICATED FOR THE TREATMENT OF PATIENTS WITH KIT (CD117) POSITIVE UNRESECTABLE AND/OR METASTATIC MALIGNANT GASTROINTESTINAL STROMAL TUMORS (GIST)


    • June 19, 2022
      ✓ 
      Pediatric exclusivity




  • Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
    Patent 7,544,799
    Issued: June 9, 2009
    Inventor(s): Zimmermann; Jürg & Sutter; Bertrand & Bürger; Hans M
    Assignee(s): Novartis AG
    The invention relates to a new crystalline form of the methanesulfonic acid addition salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of formula 1, which may be used for example for tumour therapy.
    Patent expiration dates:

    • January 16, 2019
      ✓ 
      Drug substance
      ✓ 
      Drug product


    • July 16, 2019
      ✓ 
      Pediatric exclusivity



Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • December 19, 2011 - ADJUVANT TREATMENT OF ADULT PATIENTS FOLLOWING COMPLETE GROSS RESECTION OF KIT (CD117) POSITIVE GASTOINTESTINAL STROMAL TUMORS (GIST)

    • October 19, 2013 - ORPHAN DRUG EXCLUSIVITY

    • December 19, 2015 - ORPHAN DRUG EXCLUSIVITY

See also...

  • Gleevec Consumer Information (Drugs.com)
  • Gleevec Consumer Information (Wolters Kluwer)
  • Gleevec Consumer Information (Cerner Multum)
  • Gleevec Advanced Consumer Information (Micromedex)
  • Gleevec AHFS DI Monographs (ASHP)
  • Imatinib Consumer Information (Wolters Kluwer)
  • Imatinib Consumer Information (Cerner Multum)
  • Imatinib Advanced Consumer Information (Micromedex)
  • Imatinib Mesylate AHFS DI Monographs (ASHP)

CO Zopiclone




CO Zopiclone may be available in the countries listed below.


Ingredient matches for CO Zopiclone



Eszopiclone

Zopiclone is reported as an ingredient of CO Zopiclone in the following countries:


  • Canada

International Drug Name Search

Oleptro


Oleptro is a brand name of trazodone, approved by the FDA in the following formulation(s):


OLEPTRO (trazodone hydrochloride - tablet, extended release; oral)



  • Manufacturer: ANGELINI LLC

    Approval date: February 2, 2010

    Strength(s): 150MG [RLD], 300MG

Has a generic version of Oleptro been approved?


No. There is currently no therapeutically equivalent version of Oleptro available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Oleptro. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture
    Patent 6,607,748
    Issued: August 19, 2003
    Inventor(s): Vincent; Lenaerts & Roland Herwig Friedrich; Beck & Elsie; Van Bogaert & Francois; Chouinard & Reiner; Höpcke & Cyril; Désévaux
    The present invention relates to a novel form of cross-linked high amylose starch and processes for its manufacture. Such cross-linked high amylose starch is useful as an excipient in a controlled-release pharmaceutical formulation when compressed with pharmaceutical agent(s) in a tablet. Such cross-linked high amylose starch is prepared by (a) cross-linking and chemical modification of high amylose starch, (b) gelatinization, and (c) drying to obtain a powder of said controlled release excipient. In a preferred embodiment, such cross-linked high amylose starch is prepared in the following steps: (1) granular cross-linking and additional chemical modification (e.g., hydroxypropylation) of high-amylose starch; (2) thermal gelatinization of the starch from step (1); and (3) drying the starch from step (2) to yield a powder capable of being used as a controlled release excipient.
    Patent expiration dates:

    • June 29, 2020
      ✓ 
      Drug product




  • Trazodone composition for once a day administration
    Patent 7,829,120
    Issued: November 9, 2010
    Inventor(s): Gervais; Sonia & Smith; Damon & Rahmouni; Miloud & Contamin; Pauline & Ouzerourou; Rachid & Ma; My Linh & Ferrada; Angela & Soulhi; Fouzia
    Assignee(s): Labopharm Inc.
    Labopharm Europe Limited
    Labopharm (Barbados) Limited
    The invention relates to a once a day formulation of trazodone or a trazodone derivative. The formulation contains trazodone or a trazodone derivative and a controlled release excipient so that, once administered orally, the trazodone or the trazodone derivative is maintained at a therapeutic plasma concentration from at least 1 hour to at least 24 hours after initial administration. After administration, the initial therapeutic action takes effect within the first hour and lasts at least about 24 hours. This therapeutic effect remains relatively and substantially stable for the remaining period of 24 hours. The formulations can be used for treating depression and/or sleeping disorders.
    Patent expiration dates:

    • March 27, 2027
      ✓ 
      Patent use: METHOD OF TREATING DEPRESSION
      ✓ 
      Drug product



Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • February 2, 2013 - NEW DOSAGE FORM

See also...

  • Oleptro Consumer Information (Drugs.com)
  • Oleptro Extended-Release Tablets Consumer Information (Wolters Kluwer)
  • Oleptro Consumer Information (Cerner Multum)
  • Oleptro Advanced Consumer Information (Micromedex)
  • Trazodone Consumer Information (Drugs.com)
  • Trazodone Consumer Information (Wolters Kluwer)
  • Trazodone Extended-Release Tablets Consumer Information (Wolters Kluwer)
  • Trazodone Consumer Information (Cerner Multum)
  • Trazodone Advanced Consumer Information (Micromedex)
  • Trazodone Hydrochloride AHFS DI Monographs (ASHP)

DermOtic Oil


DermOtic Oil is a brand name of fluocinolone otic, approved by the FDA in the following formulation(s):


DERMOTIC (fluocinolone acetonide - oil/drops; otic)



  • Manufacturer: HILL DERMAC

    Approval date: November 9, 2005

    Strength(s): 0.01% [RLD][AT]

Has a generic version of DermOtic Oil been approved?


Yes. The following products are equivalent to DermOtic Oil:


fluocinolone acetonide oil/drops; otic



  • Manufacturer: IDENTI PHARMS INC

    Approval date: October 17, 2011

    Strength(s): 0.01% [AT]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of DermOtic Oil. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with DermOtic Oil.

See also...

  • DermOtic Drops Consumer Information (Wolters Kluwer)
  • Fluocinolone Drops Consumer Information (Wolters Kluwer)

Myleran


Myleran is a brand name of busulfan, approved by the FDA in the following formulation(s):


MYLERAN (busulfan - tablet; oral)



  • Manufacturer: ASPEN GLOBAL

    Approved Prior to Jan 1, 1982

    Strength(s): 2MG [RLD]

Has a generic version of Myleran been approved?


No. There is currently no therapeutically equivalent version of Myleran available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Myleran. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Myleran.

See also...

  • Myleran Consumer Information (Wolters Kluwer)
  • Myleran Consumer Information (Cerner Multum)
  • Busulfan Consumer Information (Wolters Kluwer)
  • Busulfan Tablet Consumer Information (Wolters Kluwer)
  • Busulfan Consumer Information (Cerner Multum)
  • Busulfan Intravenous Advanced Consumer Information (Micromedex)
  • Busulfan AHFS DI Monographs (ASHP)

Microzide


Microzide is a brand name of hydrochlorothiazide, approved by the FDA in the following formulation(s):


MICROZIDE (hydrochlorothiazide - capsule; oral)



  • Manufacturer: WATSON LABS

    Approval date: December 27, 1996

    Strength(s): 12.5MG [RLD][AB]

Has a generic version of Microzide been approved?


Yes. The following products are equivalent to Microzide:


hydrochlorothiazide capsule; oral



  • Manufacturer: ALEMBIC PHARMS LTD

    Approval date: November 30, 2010

    Strength(s): 12.5MG [AB]


  • Manufacturer: APOTEX

    Approval date: May 16, 2008

    Strength(s): 12.5MG [AB]


  • Manufacturer: AUROBINDO PHARMA

    Approval date: September 18, 2007

    Strength(s): 12.5MG [AB]


  • Manufacturer: IPCA LABS LTD

    Approval date: April 2, 2009

    Strength(s): 12.5MG [AB]


  • Manufacturer: IVAX SUB TEVA PHARMS

    Approval date: July 13, 2005

    Strength(s): 12.5MG [AB]


  • Manufacturer: JUBILANT CADISTA

    Approval date: February 11, 2008

    Strength(s): 12.5MG [AB]


  • Manufacturer: LANNETT HOLDINGS INC

    Approval date: January 27, 2012

    Strength(s): 12.5MG [AB]


  • Manufacturer: MYLAN

    Approval date: January 28, 2000

    Strength(s): 12.5MG [AB]


  • Manufacturer: UNICHEM

    Approval date: January 19, 2010

    Strength(s): 12.5MG [AB]


  • Manufacturer: VINTAGE PHARMS

    Approval date: September 17, 2002

    Strength(s): 12.5MG [AB]


  • Manufacturer: WEST WARD

    Approval date: November 26, 2007

    Strength(s): 12.5MG [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Microzide. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Microzide.

See also...

  • Microzide Consumer Information (Wolters Kluwer)
  • Microzide Consumer Information (Cerner Multum)
  • Microzide Advanced Consumer Information (Micromedex)
  • HCTZ Consumer Information (Drugs.com)
  • Hydrochlorothiazide Consumer Information (Drugs.com)
  • Hydrochlorothiazide Consumer Information (Wolters Kluwer)
  • Hydrochlorothiazide Capsules Consumer Information (Wolters Kluwer)
  • Hydrochlorothiazide Solution Consumer Information (Wolters Kluwer)
  • Hydrochlorothiazide Consumer Information (Cerner Multum)
  • Hydrocot Advanced Consumer Information (Micromedex)
  • Zide Advanced Consumer Information (Micromedex)
  • Hydrochlorothiazide Advanced Consumer Information (Micromedex)
  • Hydrochlorothiazide AHFS DI Monographs (ASHP)

Adrenaline Hydrochloride Injection




Adrenaline Hydrochloride Injection may be available in the countries listed below.


Ingredient matches for Adrenaline Hydrochloride Injection



Epinephrine

Epinephrine hydrochloride (a derivative of Epinephrine) is reported as an ingredient of Adrenaline Hydrochloride Injection in the following countries:


  • Australia

International Drug Name Search

Biopatch




In the US, Biopatch (chlorhexidine topical) is a member of the following drug classes: antiseptic and germicides, mouth and throat products and is used to treat Gingivitis, Mucositis and Periodontitis.

US matches:

  • Biopatch

  • Biopatch w/Chlorhexidine Gluconate

Ingredient matches for Biopatch



Chlorhexidine

Chlorhexidine digluconate (a derivative of Chlorhexidine) is reported as an ingredient of Biopatch in the following countries:


  • United States

International Drug Name Search

Zipsor


Zipsor is a brand name of diclofenac, approved by the FDA in the following formulation(s):


ZIPSOR (diclofenac potassium - capsule; oral)



  • Manufacturer: XANODYNE PHARM

    Approval date: June 16, 2009

    Strength(s): 25MG [RLD]

Has a generic version of Zipsor been approved?


No. There is currently no therapeutically equivalent version of Zipsor available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zipsor. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Oral liquid compositions
    Patent 6,365,180
    Issued: April 2, 2002
    Inventor(s): Glenn A.; Meyer & Laura A.; Trespidi & Edward S.; Wilson & Christy M.; Clark & Ashok J.; Desai & Frederick D.; Sancilio
    The present invention relates to novel, liquid and semi-solid pharmaceutical compositions which can be administered in liquid form or can be used for preparing capsules containing such pharmaceutical compositions. Also provided are methods of using and processes for preparing the pharmaceutical compositions of the present invention.
    Patent expiration dates:

    • July 15, 2019
      ✓ 
      Patent use: NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN
      ✓ 
      Drug product




  • Method of treating post-surgical acute pain
    Patent 7,662,858
    Issued: February 16, 2010
    Inventor(s): Kowalski; Mark M. & Young; James L. & Moore; Keith A.
    Assignee(s): aaiPharma, Inc.
    A method is provided for treating pain in patients recovering from post-surgical trauma by administering between about 13 to about 30 mg of diclofenac potassium in a liquid dispersible formulation over a period of at least 24 hours, wherein the daily total amount of diclofenac potassium administered is less than or equal to about 100 mg. The method is particularly useful in treating acute pain in bunionectomy patients.
    Patent expiration dates:

    • February 24, 2029
      ✓ 
      Patent use: NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN




  • Method of treating post-surgical acute pain
    Patent 7,884,095
    Issued: February 8, 2011
    Inventor(s): Kowalski; Mark M. & Young; James L. & Moore; Keith A.
    Assignee(s): aaiPharma Inc.
    A method is provided for treating pain in patients recovering from post-surgical trauma by administering between about 13 to about 30 mg of diclofenac potassium in a liquid dispersible formulation over a period of at least 24 hours, wherein the daily total amount of diclofenac potassium administered is less than or equal to about 100 mg. The method is particularly useful in treating acute pain in bunionectomy patients.
    Patent expiration dates:

    • February 24, 2029
      ✓ 
      Patent use: NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN




  • Method of treating post-surgical acute pain
    Patent 7,939,518
    Issued: May 10, 2011
    Inventor(s): Kowalski; Mark M. & Young; James L. & Moore; Keith A.
    Assignee(s): Aaipharma Inc.
    A method is provided for treating pain in patients recovering from post-surgical trauma by administering between about 13 to about 30 mg of diclofenac potassium in a liquid dispersible formulation over a period of at least 24 hours, wherein the daily total amount of diclofenac potassium administered is less than or equal to about 100 mg. The method is particularly useful in treating acute pain in bunionectomy patients.
    Patent expiration dates:

    • February 24, 2029
      ✓ 
      Patent use: NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN




  • Method of treating post-surgical acute pain
    Patent 8,110,606
    Issued: February 7, 2012
    Inventor(s): Kowalski; Mark M. & Young; James L. & Moore; Keith A.
    Assignee(s): Aaipharma Services Corp.
    A method is provided for treating pain in patients recovering from post-surgical trauma by administering between about 13 to about 30 mg of diclofenac potassium in a liquid dispersible formulation over a period of at least 24 hours, wherein the daily total amount of diclofenac potassium administered is less than or equal to about 100 mg. The method is particularly useful in treating acute pain in bunionectomy patients.
    Patent expiration dates:

    • February 24, 2029
      ✓ 
      Patent use: NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN



Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • June 16, 2012 - NEW DOSAGE FORM

See also...

  • Zipsor Consumer Information (Drugs.com)
  • Zipsor Consumer Information (Wolters Kluwer)
  • Zipsor Consumer Information (Cerner Multum)
  • Zipsor Advanced Consumer Information (Micromedex)
  • Diclofenac Consumer Information (Drugs.com)
  • Diclofenac Consumer Information (Wolters Kluwer)
  • Diclofenac Enteric-Coated Tablets Consumer Information (Wolters Kluwer)
  • Diclofenac Extended-Release Tablets Consumer Information (Wolters Kluwer)
  • Diclofenac Immediate-Release Tablets Consumer Information (Wolters Kluwer)
  • Diclofenac Potassium Powder Packets Consumer Information (Wolters Kluwer)
  • Diclofenac Consumer Information (Cerner Multum)
  • Diclofenac Advanced Consumer Information (Micromedex)
  • Diclofenac Potassium AHFS DI Monographs (ASHP)
  • Diclofenac Sodium AHFS DI Monographs (ASHP)
  • Diclofenac epolamine AHFS DI Monographs (ASHP)

Tradjenta


Tradjenta is a brand name of linagliptin, approved by the FDA in the following formulation(s):


TRADJENTA (linagliptin - tablet; oral)



  • Manufacturer: BOEHRINGER INGELHEIM

    Approval date: May 2, 2011

    Strength(s): 5MG [RLD]

Has a generic version of Tradjenta been approved?


No. There is currently no therapeutically equivalent version of Tradjenta available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Tradjenta. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals
    Patent 6,303,661
    Issued: October 16, 2001
    Inventor(s): Demuth; Hans-Ulrich & Rosche; Fred & Schmidt; Joem & Pauly; Robert P. & McIntosh; Christopher H. S. & Pederson; Ray A.
    Assignee(s): Probiodrug
    Novel therapeutic regimens are provided which comprise the administration of therapeutically effective amounts of an inhibitor to dipeptidyl peptidase (DP-IV) or enzymes of similar activity whereby their ability to degrade the incretins, GLP-1 and GIP, is reduced. As a result hyperglycemia, such as that accompanying food intake may be reduced due to improved insulin release. A preferred therapeutic regimen amongst a number of routes of administration and inhibitors that may be used comprises the oral administration of isoleucyl thiazolidine.
    Patent expiration dates:

    • April 24, 2017
      ✓ 
      Patent use: METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASTE-IV INHIBITOR




  • Method of regulating glucose metabolism, and reagents related thereto
    Patent 6,890,898
    Issued: May 10, 2005
    Inventor(s): Bachovchin; William W. & Plaut; Andrew G. & Drucker; Daniel
    Assignee(s): Trustees of Tufts College
    1149336 Ontario Inc.
    New England Medical Center Hospitals, Inc.
    The present invention provides methods and compositions for modification and regulation of glucose and lipid metabolism, generally to reduce insulin resistance, hyperglycemia, hyperinsulinemia, obesity, hyperlipidemia, hyperlipoprotein-emia (such as chylomicrons, VLDL and LDL), and to regulate body fat and more generally lipid stores, and, more generally, for the improvement of metabolism disorders, especially those associated with diabetes, obesity and/or atherosclerosis.
    Patent expiration dates:

    • February 2, 2019
      ✓ 
      Patent use: TREATMENT OF TYPE 2 DIABETES MELLITUS




  • Method of regulating glucose metabolism, and reagents related thereto
    Patent 7,078,381
    Issued: July 18, 2006
    Inventor(s): Bachovchin; William W. & Plaut; Andrew G. & Drucker; Daniel
    Assignee(s): Trustees of Tufts College
    The present invention provides methods and compositions for modifying glucose metabolism and treating Type II diabetes in an animal, along with modifying metabolism of a peptide hormone in an animal. Compositions disclosed herein comprise one or more peptides and/or peptide analogs which include a functional group that reacts with an active site residue of a protease.
    Patent expiration dates:

    • February 2, 2019
      ✓ 
      Patent use: TREATMENT OF TYPE 2 DIABETES MELLITUS




  • 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
    Patent 7,407,955
    Issued: August 5, 2008
    Inventor(s): Himmelsbach; Frank & Langkopf; Elke & Eckhardt; Matthias & Mark; Michael & Maier; Roland & Lotz; Ralf R. H. & Tadayyon; Mohammad
    Assignee(s): Boehringer Ingelheim Pharma GmbH & Co., KG
    The present invention relates to substituted xanthines of general formula wherein R1 to R3 are defined as in claims 1 to 16, the tautomers, the stereoisomers, the mixtures, the prodrugs thereof and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).
    Patent expiration dates:

    • August 12, 2023
      ✓ 
      Drug substance
      ✓ 
      Drug product




  • Method of regulating glucose metabolism, and reagents related thereto
    Patent 7,459,428
    Issued: December 2, 2008
    Inventor(s): Bachovchin; William W. & Plaut; Andrew G. & Drucker; Daniel
    Assignee(s): Trustees of Tufts College
    New England Medical Center Hospitals, Inc.
    1149336 Ontario, Inc.
    One aspect of the present invention relates to a method for treating Type II diabetes in an animal, comprising conjointly administering to the animal metformin and an inhibitor of dipeptidylpeptidase IV or a pharmaceutically acceptable salt thereof in an amount sufficient to treat Type II diabetes of the animal.
    Patent expiration dates:

    • February 2, 2019
      ✓ 
      Patent use: TREATMENT OF TYPE 2 DIABETES MELLITUS



Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • May 2, 2016 - NEW CHEMICAL ENTITY

See also...

  • Tradjenta Consumer Information (Drugs.com)
  • Tradjenta Consumer Information (Wolters Kluwer)
  • Tradjenta Consumer Information (Cerner Multum)
  • Tradjenta Advanced Consumer Information (Micromedex)
  • Linagliptin Consumer Information (Wolters Kluwer)
  • Linagliptin Consumer Information (Cerner Multum)
  • Linagliptin Advanced Consumer Information (Micromedex)

Pro-Chlo Liquid


Pronunciation: FEN-il-EF-rin/pir-IL-a-meen/KLOE-fe-DYE-a-nol
Generic Name: Phenylephrine/Pyrilamine/Chlophedianol
Brand Name: Pro-Chlo


Pro-Chlo Liquid is used for:

Relieving symptoms of sinus congestion, runny nose, sneezing, itchy nose or throat, itchy or watery eyes, and cough caused by colds, hay fever, and allergies. It may also be used for other conditions as determined by your doctor.


Pro-Chlo Liquid is a decongestant, antihistamine, and cough suppressant combination. The decongestant works by constricting blood vessels and reducing swelling in the nasal passages. The antihistamine works by blocking the action of histamine, which helps reduce symptoms such as watery eyes and sneezing. The cough suppressant works in the brain to help decrease the cough reflex to reduce a dry cough.


Do NOT use Pro-Chlo Liquid if:


  • you are allergic to any ingredient in Pro-Chlo Liquid

  • you have severe or uncontrolled high blood pressure, severe heart blood vessel disease, rapid heartbeat, or severe heart problems

  • you are unable to urinate or are having an asthma attack

  • you are taking droxidopa, sodium oxybate (GHB), or if you have taken furazolidone or a monoamine oxidase inhibitor (MAOI) (eg, phenelzine) within the last 14 days

Contact your doctor or health care provider right away if any of these apply to you.



Before using Pro-Chlo Liquid:


Some medical conditions may interact with Pro-Chlo Liquid. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:


  • if you are pregnant, planning to become pregnant, or are breast-feeding

  • if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement

  • if you have allergies to medicines, foods, or other substances

  • if you have a history of adrenal gland problems (eg, adrenal gland tumor), heart problems (eg, fast, slow, or irregular heartbeat; heart disease), high or low blood pressure, low blood volume, diabetes, blood vessel problems, a stroke, glaucoma or increased pressure in the eye, seizures, thyroid problems, or trouble sleeping

  • if you have a history of asthma, chronic obstructive pulmonary disease (COPD), or other lung or breathing problems (eg, chronic bronchitis, emphysema), trouble breathing when you sleep (sleep apnea), or chronic cough, or if your cough occurs with large amounts of mucus

  • if you have a history of stomach or bowel ulcers; a blockage of your stomach, bladder, or bowel; kidney problems; an enlarged prostate or other prostate problems; or trouble urinating

  • if you take medicine for high blood pressure

Some MEDICINES MAY INTERACT with Pro-Chlo Liquid. Tell your health care provider if you are taking any other medicines, especially any of the following:


  • Digoxin or droxidopa because the risk of irregular heartbeat or a heart attack may be increased

  • Beta-blockers (eg, propranolol), catechol-O-methyltransferase (COMT) inhibitors (eg, tolcapone), furazolidone, linezolid, MAOIs (eg, phenelzine), sodium oxybate (GHB), or tricyclic antidepressants (eg, amitriptyline) because they may increase the risk of Pro-Chlo Liquid's side effects

  • Bromocriptine or hydantoins (eg, phenytoin) because the risk of their side effects may be increased by Pro-Chlo Liquid

  • Guanadrel, guanethidine, mecamylamine, methyldopa, or reserpine because their effectiveness may be decreased by Pro-Chlo Liquid

This may not be a complete list of all interactions that may occur. Ask your health care provider if Pro-Chlo Liquid may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.


How to use Pro-Chlo Liquid:


Use Pro-Chlo Liquid as directed by your doctor. Check the label on the medicine for exact dosing instructions.


  • Take Pro-Chlo Liquid by mouth with or without food. If stomach upset occurs, take with food to reduce stomach irritation.

  • Use a measuring device marked for medicine dosing. Ask your pharmacist for help if you are unsure of how to measure your dose.

  • Drink plenty of water while taking Pro-Chlo Liquid.

  • If you miss a dose of Pro-Chlo Liquid and you are taking it regularly, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.

Ask your health care provider any questions you may have about how to use Pro-Chlo Liquid.



Important safety information:


  • Pro-Chlo Liquid may cause drowsiness, dizziness, or blurred vision. These effects may be worse if you take it with alcohol or certain medicines. Use Pro-Chlo Liquid with caution. Do not drive or perform other possibly unsafe tasks until you know how you react to it.

  • Check with your doctor before you use medicines that may cause drowsiness (eg, sleep aids, muscle relaxers) while you are using Pro-Chlo Liquid; it may add to their effects. Ask your pharmacist if you have questions about which medicines may cause drowsiness.

  • Do not drink alcohol while you are taking Pro-Chlo Liquid.

  • Do not take diet or appetite control medicines while you are taking Pro-Chlo Liquid without checking with your doctor.

  • Pro-Chlo Liquid has a decongestant, antihistamine, and cough suppressant in it. Before you start any new medicine, including medicine used on the skin, check the label to see if it has a decongestant, antihistamine, or cough suppressant in it too. If it does or if you are not sure, check with your doctor or pharmacist.

  • Do not use Pro-Chlo Liquid for cough with a lot of mucus. Do not use for long-term cough (eg, caused by asthma, emphysema, smoking). However, you may use it for these conditions if your doctor tells you to.

  • Do NOT take more than the recommended dose or use for longer than recommended without checking with your doctor.

  • If new symptoms occur, or if cough or nasal congestion persists for more than 1 week, gets worse or returns, or occurs along with a fever, rash, or persistent headache, check with your doctor. A persistent cough may be a sign of a serious condition.

  • Pro-Chlo Liquid may cause you to become sunburned more easily. Avoid the sun, sunlamps, or tanning booths until you know how you react to Pro-Chlo Liquid. Use a sunscreen or wear protective clothing if you must be outside for more than a short time.

  • Pro-Chlo Liquid may interfere with skin allergy tests. If you are scheduled for a skin test, talk to your doctor. You may need to stop taking Pro-Chlo Liquid for a few days before the tests.

  • Tell your doctor or dentist that you take Pro-Chlo Liquid before you receive any medical or dental care, emergency care, or surgery.

  • Use Pro-Chlo Liquid with caution in the ELDERLY; they may be more sensitive to its effects, especially confusion, dizziness, drowsiness, dry mouth, excitability, low blood pressure, and trouble urinating.

  • Caution is advised when using Pro-Chlo Liquid in CHILDREN; they may be more sensitive to its effects, especially excitability.

  • Pro-Chlo Liquid should not be used in CHILDREN younger than 6 years old without first checking with the child's doctor; safety and effectiveness in these children have not been confirmed.

  • PREGNANCY and BREAST-FEEDING: If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Pro-Chlo Liquid while you are pregnant. It is not known if Pro-Chlo Liquid is found in breast milk. If you are or will be breast-feeding while you use Pro-Chlo Liquid, check with your doctor. Discuss any possible risks to your baby.


Possible side effects of Pro-Chlo Liquid:


All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:



Anxiety; constipation; diarrhea; dizziness; drowsiness; dry mouth, nose, or throat; excitability; headache; increased sweating; loss of appetite; nausea; trouble sleeping; upset stomach; vomiting; weakness.



Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); difficulty urinating or inability to urinate; fast or irregular heartbeat; fever, chills, or persistent sore throat; hallucinations; loss of coordination; mental or mood changes (eg, depression, nervousness); seizures; severe dryness of the mouth, nose, and throat; severe or persistent dizziness, drowsiness, light-headedness, or headache; severe or persistent trouble sleeping; shortness of breath; tremor; unusual bruising or bleeding; unusual tiredness or weakness; vision problems (eg, double vision, severe or persistent blurred vision).



This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.



If OVERDOSE is suspected:


Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include blurred vision; confusion; flushing; hallucinations; mental or mood changes; muscle spasms; seizures; severe dizziness, light-headedness, or headache; severe drowsiness; trouble breathing; unusually fast, slow, or irregular heartbeat; vomiting.


Proper storage of Pro-Chlo Liquid:

Store Pro-Chlo Liquid at room temperature, between 59 and 86 degrees F (15 and 30 degrees C). Store away from heat, moisture, and light. Do not store in the bathroom. Keep Pro-Chlo Liquid out of the reach of children and away from pets.


General information:


  • If you have any questions about Pro-Chlo Liquid, please talk with your doctor, pharmacist, or other health care provider.

  • Pro-Chlo Liquid is to be used only by the patient for whom it is prescribed. Do not share it with other people.

  • If your symptoms do not improve or if they become worse, check with your doctor.

  • Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Pro-Chlo Liquid. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.



Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

Fenofibrat LPH




Fenofibrat LPH may be available in the countries listed below.


Ingredient matches for Fenofibrat LPH



Fenofibrate

Fenofibrate is reported as an ingredient of Fenofibrat LPH in the following countries:


  • Romania

International Drug Name Search

Viagra


Viagra is a brand name of sildenafil, approved by the FDA in the following formulation(s):


VIAGRA (sildenafil citrate - tablet; oral)



  • Manufacturer: PFIZER IRELAND

    Approval date: March 27, 1998

    Strength(s): EQ 100MG BASE [RLD], EQ 25MG BASE, EQ 50MG BASE

Has a generic version of Viagra been approved?


No. There is currently no therapeutically equivalent version of Viagra available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Viagra. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Pyrazolopyrimidinone antianginal agents
    Patent 5,250,534
    Issued: October 5, 1993
    Inventor(s): Bell; Andrew S. & Brown; David & Terrett; Nicholas K.
    Assignee(s): Pfizer Inc.
    Compounds of the formula: ##STR1## wherein R.sup.1 is H, C.sub.1 -C.sub.3 alkyl, C.sub.3 -C.sub.5 cycloalkyl or C.sub.1 -C.sub.3 perfluoroalkyl; R.sup.2 is H, C.sub.1 -C.sub.6 alkyl optionally substituted by OH, C.sub.1 -C.sub.3 alkoxy or C.sub.3 -C.sub.6 cycloalkyl, or C.sub.1 -C.sub.3 perfluoroalkyl; R.sup.3 is C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 alkenyl, C.sub.3 -C.sub.6 alkynyl, C.sub.3 -C.sub.7 cycloalkyl, C.sub.1 -C.sub.6 perfluoroalkyl or (C.sub.3 -C.sub.6 cycloalkyl)C.sub.1 -C.sub.6 alkyl; R.sup.4 taken together with the nitrogen atom to which it is attached completes a pyrrolidinyl, piperidino, morpholino, or 4-N-(R.sup.6)-piperazinyl group; R.sup.5 is H, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.3 alkoxy, NR.sup.7 R.sup.8, or CONR.sup.7 R.sup.8 ; R.sup.6 is H, C.sub.1 -C.sub.6 alkyl, (C.sub.1 -C.sub.3 alkoxy) C.sub.2 - C.sub.6 alkyl, hydroxy C.sub.2 -C.sub.6 alkyl, (R.sup.7 R.sup.8 N)C.sub.2 -C.sub.6 alkyl, (R.sup.7 R.sup.8 NCO)C.sub.1 -C.sub.6 alkyl, CONR.sup.7 R.sup.8, CSNR.sup.7 R.sup.8 or C(NH)NR.sup.7 R.sup.8 ; R.sup.7 and R.sup.8 are each independently H, C.sub.1 -C.sub.4 alkyl, (C.sub.1 -C.sub.3 alkoxy)C.sub.2 -C.sub.4 alkyl or hydroxy C.sub.2 -C.sub.4 alkyl; and pharmaceutically acceptable salts thereof, are selective cGMP PDE inhibitors useful in the treatment of cardiovascular disorders such as angina, hypertension, heart failure and atherosclerosis.
    Patent expiration dates:

    • March 27, 2012


    • September 27, 2012
      ✓ 
      Pediatric exclusivity




  • Pyrazolopyrimidinones for the treatment of impotence
    Patent 6,469,012
    Issued: October 22, 2002
    Inventor(s): Peter; Ellis & Nicholas Kenneth; Terrett
    Assignee(s): Pfizer Inc
    The use of a compound of formula (I) wherein R1 is H; C1-C3 alkyl; C1-C3 perfluoroalkyl; or C3-C5 cycloalkyl; R2 is H; optionally substituted C1-C6 alkyl; C1-C3 perfluoroalkyl; or C3-C6 cycloalkyl; R3 is optionally substituted C1-C6 alkyl; C1-C6 perfluoroalkyl; C3-C5 cycloalkyl; C3-C6 alkenyl; or C3-C6 alkynyl; R4 is optionally substituted C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkanoyl, (hydroxy)C2-C4 alkyl or (C2-C3 alkoxy)C1-C2 alkyl; CONR5R6; CO2R7; halo; NR5R6; NHSO2NR5R6; NHSO2R8; SO2NR9R10; or phenyl, pyridyl, pyrimidinyl, imidazolyl, oxazolyl, thiazolyl, thienyl or triazolyl any of which is optionally substituted with methyl; R5 and R6 are each independently H or C1-C4 alkyl, or together with the nitrogen atom to which they are attached form an optionally substituted pyrrolidinyl, piperidino, morpholino, 4-N(R11)-piperazinyl or imidazolyl group; R7 is H or C1-C4 alkyl; R8 is optionally substituted C1-C3 alkyl; R9 and R10 together with the nitrogen atom to which they are attached form an optionally substituted pyrrolidinyl, piperidino, morpholino or 4-N(R12)-piperazinyl group; R11 is H; optionally substituted C1-C3 alkyl; (hydroxy)C2-C3 alkyl; or C1-C4 alkanoyl; R12 is H; optionally substituted C1-C6 alkyl; CONR13R14; CSNR13R14; or C(NH)NR13R14; and R?13? and R14 are each independently H; C1-C4 alkyl; or substituted C2-C4 alkyl; or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing either entity, for the manufacture of a medicament for the curative or prophylactic treatment of erectile dysfunction in a male animal, including man; a pharmaceutical composition for said treatment; and a method of said treatment of said male animal with said pharmaceutical composition or with said either entity.
    Patent expiration dates:

    • October 22, 2019
      ✓ 
      Patent use: TREATMENT OF ERECTILE DYSFUNCTION


    • April 22, 2020
      ✓ 
      Pediatric exclusivity



See also...

  • Viagra Consumer Information (Drugs.com)
  • Viagra Consumer Information (Wolters Kluwer)
  • Viagra Consumer Information (Cerner Multum)
  • Viagra Advanced Consumer Information (Micromedex)
  • Sildenafil Consumer Information (Wolters Kluwer)
  • Sildenafil Injection Consumer Information (Wolters Kluwer)
  • Sildenafil Consumer Information (Cerner Multum)
  • Sildenafil Advanced Consumer Information (Micromedex)
  • Sildenafil Intravenous Advanced Consumer Information (Micromedex)
  • Sildenafil Citrate AHFS DI Monographs (ASHP)

Bupivacaine Hydrochloride Baxter




Bupivacaine Hydrochloride Baxter may be available in the countries listed below.


Ingredient matches for Bupivacaine Hydrochloride Baxter



Bupivacaine

Bupivacaine hydrochloride (a derivative of Bupivacaine) is reported as an ingredient of Bupivacaine Hydrochloride Baxter in the following countries:


  • Greece

International Drug Name Search

Daraprim


Daraprim is a brand name of pyrimethamine, approved by the FDA in the following formulation(s):


DARAPRIM (pyrimethamine - tablet; oral)



  • Manufacturer: COREPHARMA

    Approved Prior to Jan 1, 1982

    Strength(s): 25MG [RLD]

Has a generic version of Daraprim been approved?


No. There is currently no therapeutically equivalent version of Daraprim available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Daraprim. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Daraprim.

See also...

  • Daraprim Consumer Information (Wolters Kluwer)
  • Daraprim Consumer Information (Cerner Multum)
  • Daraprim Advanced Consumer Information (Micromedex)
  • Pyrimethamine Consumer Information (Wolters Kluwer)
  • Pyrimethamine Consumer Information (Cerner Multum)
  • Pyrimethamine Advanced Consumer Information (Micromedex)

Depen


Depen is a brand name of penicillamine, approved by the FDA in the following formulation(s):


DEPEN (penicillamine - tablet; oral)



  • Manufacturer: MEDA PHARMS

    Approved Prior to Jan 1, 1982

    Strength(s): 250MG [RLD]

Has a generic version of Depen been approved?


No. There is currently no therapeutically equivalent version of Depen available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Depen. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Depen.

See also...

  • Depen Consumer Information (Wolters Kluwer)
  • Depen Consumer Information (Cerner Multum)
  • Depen Advanced Consumer Information (Micromedex)
  • Penicillamine Consumer Information (Wolters Kluwer)
  • Penicillamine Consumer Information (Cerner Multum)
  • Penicillamine Advanced Consumer Information (Micromedex)
  • Penicillamine AHFS DI Monographs (ASHP)

Benzamycin Pak


See also: Generic Benzamycin


Benzamycin Pak is a brand name of benzoyl peroxide/erythromycin topical, approved by the FDA in the following formulation(s):


BENZAMYCIN PAK (benzoyl peroxide; erythromycin - gel; topical)



  • Manufacturer: SANOFI AVENTIS US

    Approval date: November 27, 2000

    Strength(s): 5%;3% [RLD]

Has a generic version of Benzamycin Pak been approved?


No. There is currently no therapeutically equivalent version of Benzamycin Pak available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Benzamycin Pak. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Benzamycin Pak.

See also...

  • Benzamycin Pak Gel Consumer Information (Wolters Kluwer)
  • Benzamycin Pak Topical Advanced Consumer Information (Micromedex)
  • Benzoyl Peroxide/Erythromycin Gel Consumer Information (Wolters Kluwer)
  • Benzoyl peroxide and erythromycin topical Consumer Information (Cerner Multum)
  • Erythromycin and benzoyl peroxide Topical Advanced Consumer Information (Micromedex)